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Chemotherapy-free treatments: are we
ready for prime time?
Epithelial ovarian cancer (EOC) is most frequently diagnosed at
an advanced stage and, despite high response rates to initial
taxane-platinum-based chemotherapy, more than 70% of
patients will develop recurrent disease and will receive several
chemotherapy treatments. At present, the 5-year overall survival
(OS) for women diagnosed with stage III–IV disease is46% and
patients with genetic impairments of DNA repair pathways
[BRCA mutations and in general homologous recombination de-
ficiency (HRD)] live longer and possibly will receive even more
lines of chemotherapy [1].
The cumulative toxicity of chemotherapy, particularly if
platinum-based, in terms of neurotoxicity, nephrotoxicity and
myelotoxicity, is a limiting factor in patients scheduled to receive
multiple lines of treatment. Moreover, allergic reactions to plati-
num, whose frequency increases with multiple treatment lines, is
a great challenge, particularly in long-surviving patients. Finally,
the risk of secondary tumors, particularly in HRD patients, seems
to be related to the number of previous chemotherapy lines—and
platinum in particular—thus introducing important concerns on
the long-term safety of patients [2].
Based on these issues, the development of active and well-
tolerated chemotherapy-free regimens may provide an attractive
alternative for patients who will receive multiple lines of therapy.
The initial discovery that poly-adenosine diphosphate [ADP]-
ribose polymerase (PARP) inhibitor enhance anticancer activity
in vitro in BRCA mutated (BRCAmut) cancers led to the initial
testing of PARP inhibitors as single agents and as maintenance
treatment in BRCAmut cancers, platinum-sensitive and
platinum-responsive, and their subsequent regulatory approval
in these settings [3]. More recently, this strategy has been broad-
ened to also include all patients in the platinum-sensitive setting
regardless of the HRD signature.
PARP inhibitors work based on the concept of synthetic lethal-
ity, which refers to the presence in the cell of an inherent vulnera-
bility (HRD) that is by itself not lethal, but when combined with
another genetic event may become lethal. Some conditions, such as
hypoxia, may artificially create or enhance a condition of genomic
instability. Tumor cells exposed to chronic hypoxia following anti-
angiogenic treatment [4] have been shown to acquire defects in ho-
mologous recombination (HR) DNA repair, through
downregulation of HR repair proteins such as BRCA1 and RAD51,
resulting in an increased sensitivity to PARP inhibition [5].
Cediranib, a potent antiangiogenic tyrosine kinase inhibitor of
VEGFR-1/2/3 has demonstrated significant antitumor activity and
delayed tumor progression when given as maintenance therapy in
women with recurrent ovarian cancer [6]. The primary analysis of
a randomized phase II trial in 90 recurrent platinum-sensitive
ovarian cancer patients suggested that the combination of cedira-
nib and olaparib, a PARP inhibitor [1], was synergistic with a
6-month increase in progression-free survival (PFS) compared
with olaparib alone [7].
In a retrospective analysis of the BRCAmut and BRCAwt sub-
groups, the difference in PFS was greatest in BRCAwt women
(HR 0.32 compared with HR 0.55 in BRCAmut). Grade 3 or
higher adverse events were observed in 70% of patients treated
with the initial dose of cediranib 30 mg in the combination, the
most frequent being diarrhea, fatigue and hypertension.
However, compliance with treatment was very high (97%) due to
dose reduction of cediranib in 77% of patients [7].
In the update analysis at a median follow-up of 46 months pub-
lished in this issue, Liu et al. [8] confirmed a significantly longer
median PFS with cediranib/olaparib compared with olaparib
alone of 16.5 versus 8.2 months (HR 0.50; P¼ 0.007). Subset
analyses in BRCAwt/unknown patients demonstrated a statisti-
cally significant improvement in PFS (23.7 versus 5.7 months,
P¼ 0.002) and OS (37.8 versus 23.0 months, P¼ 0.047), without
OS differences in the overall study population (44.2 versus
33.3 months, HR 0.64; P¼ 0.11).
This study reported that a chemotherapy-free treatment in a
population of platinum-sensitive recurrent EOC can produce the
same oncologic outcomes interms of PFS and OS of the most
commonly used chemotherapy treatments [9], thus representing
a potentially new strategy. Based on the same assumptions of
other chemotherapy-free combinations, the ENGOT-OV24/
AVANOVA study is testing the combination of bevacizumab and
niraparib in the platinum-sensitive setting (NCT02354131).
Immune checkpoint inhibitors have led to important clinical
advances in the treatment of some solid tumors, but
unfortunately have reported limited single-agent activity in ovar-
ian cancer leading to the opportunity to test combination strate-
gies [10]. The possibility of combining PARP inhibitors and
anticheckpoint blockade appears very promising; preclinical
studies showed DNA damage promotes neoantigen expression
[11] and it is possible that increased DNA damage by
PARPi would yield greater mutational burden and expand neo-
antigen expression, leading to greater immune recognition of the
tumor.
The TOPACIO trial [12] has tested the combination of
niraparib and pembrolizumab in a population of triple-
negative breast cancer and recurrent platinum-resistant EOC
(NCT02657889). Among the 60 evaluable EOC patients, an over-
all response rate (ORR) of 25% and a disease control rate of 68%
were reported. Moreover, responses were not dependent on bio-
marker status; ORR was 26% in BRCAwt patients and 29% in
patients with HRD-positive tumors. The combination was well-
tolerated with an incidence of grade 3/4 thrombocytopenia (9%),
anemia (19%) and neutropenia (6%).
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With the same strategy, the combination of durvalumab and
olaparib registered a disappointing 15% ORR in a population of
34 recurrent, mainly platinum-resistant, heavily pretreated EOC
patients [13] while an outstanding 71% RR was reported with the
same combination in a population of recurrent, platinum-
sensitive BRCAmt EOC patients. This suggests that appropriate
selection of the setting of disease and patient population is im-
portant [14].
At present, chemotherapy-free treatments are a clinical reality:
olaparib has been approved by FDA as a single agent for the treat-
ment of BRCAmut-EOC treated with at least three previous che-
motherapy lines. Rucaparib, another PARP inhibitor, has been
approved by FDA and EMA in the same setting in a less pre-
treated BRCAmut population (at least two previous chemother-
apy lines) based on the results of two phase II studies reporting
ORR in line with that achieved with standard chemotherapy and
a completely different toxicity profile [15].
Nevertheless, what clinicians and patients should be con-
scious of is that chemotherapy-free treatments still present
some tricky and sometimes life-threatening toxicities that
may significantly impact patients quality of life, which could
greatly reduce their compliance to treatment (particularly in
the case of orally administered drugs) with potential conse-
quences on efficacy.
Toxicity still remains a concern with respect to these new onco-
logic treatments: after definitively abandoning the initial idea
they lacked toxicity; the scientific community has learned in the
last years to manage different, but not less impactful, toxicities of
PARP inhibitors, antiangiogenic agents and immunocheckpoint
inhibitors. There is sometimes the clear sense that phase I trials
fail to identify the appropriate dosage, and that often these drugs
have been developed according to the old criterium of the maxi-
mum tolerated dosage, rather than minimum effective dose,
which avoids any further consideration of flat dose immunother-
apy, which appear sometimes senseless in addition to being
highly costly [16].
Finally, the appropriate setting of disease and patients se-
lection remains mandatory even for chemotherapy-free strat-
egies: it is very difficult to imagine in the future that
carboplatin-paclitaxel will be deleted from first-line treatment
of ovarian cancer, while it appears much more convincing
that the combination of a checkpoint inhibitor and a PARP
inhibitor or an anti-VEGF and a PARP inhibitors may be
substitutes for chemotherapy in the treatment of recurrent
disease, especially in later lines.
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